Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.33
-0.1200-4.90%
Post-market: 2.440.1126+4.83%19:59 EDT
Volume:1.70M
Turnover:4.07M
Market Cap:279.60M
PE:-2.21
High:2.51
Open:2.46
Low:2.32
Close:2.45
52wk High:3.23
52wk Low:0.9335
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.95
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.82
PE(LYR):-2.03

Loading ...

Fate Therapeutics - Enrollment in Phase 1/2 Study of FT839 Expected to Begin in H2 2026

THOMSON REUTERS
·
Jul 09

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT839 Trial to Initially Target Rheumatoid Arthritis, Vasculitis, Myositis, Lupus, Systemic Sclerosis

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT819 Also Being Evaluated in Sle; Phase 2 Trial Planned in Lupus Nephritis

THOMSON REUTERS
·
Jul 06

Fate Therapeutics Reports Preliminary FT819 CAR-T Data Showing Skin Score Improvement in Systemic Sclerosis Patients

Reuters
·
Jul 06

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

GlobeNewswire
·
Jul 02

H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 24

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jun 22

Fate Therapeutics Shareholders Back Directors and Governance Plans

TIPRANKS
·
Jun 16

Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan

Reuters
·
Jun 16

BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of Directors

Reuters
·
Jun 15

Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board

Reuters
·
Jun 15

Press Release: Fate Therapeutics Appoints Laura Hamill to Board of Directors

Dow Jones
·
Jun 15

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 09

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 08

Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Jun 06

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

TIPRANKS
·
Jun 05

Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability

TIPRANKS
·
Jun 05

Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen

Reuters
·
Jun 04